Phase II Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia

Trial Profile

Phase II Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Ixazomib (Primary) ; Dexamethasone; Dexamethasone; Rituximab
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Dec 2016 Preliminary results (n=24) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 28 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top